Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]
It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]
- Market Cap ₹ 1,02,861 Cr.
- Current Price ₹ 3,039
- High / Low ₹ 3,591 / 2,488
- Stock P/E 55.2
- Book Value ₹ 222
- Dividend Yield 0.92 %
- ROCE 23.2 %
- ROE 24.2 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 73.8%
- Company's working capital requirements have reduced from 72.1 days to 53.1 days
Cons
- Stock is trading at 13.7 times its book value
- Promoter holding has decreased over last quarter: -2.94%
- The company has delivered a poor sales growth of 6.93% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE 250 LargeMidCap Index Nifty India Manufacturing BSE 100 LargeCap TMC Index Nifty200 Momentum 30 Nifty LargeMidcap 250
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3,203 | 4,172 | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,302 | |
2,506 | 3,216 | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,662 | |
Operating Profit | 697 | 955 | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,640 |
OPM % | 22% | 23% | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% |
1 | 34 | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | 72 | |
Interest | 34 | 59 | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 276 |
Depreciation | 83 | 87 | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 797 |
Profit before tax | 582 | 844 | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,639 |
Tax % | 25% | 21% | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | |
435 | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,862 | |
EPS in Rs | 12.79 | 19.62 | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 55.02 |
Dividend Payout % | 45% | 25% | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 7% |
3 Years: | 10% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 22% |
3 Years: | 8% |
TTM: | 30% |
Stock Price CAGR | |
---|---|
10 Years: | 19% |
5 Years: | 23% |
3 Years: | 30% |
1 Year: | 16% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 21% |
3 Years: | 21% |
Last Year: | 24% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 42 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 |
Reserves | 1,380 | 1,818 | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,335 |
693 | 1,132 | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,128 | |
1,638 | 1,988 | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 4,456 | |
Total Liabilities | 3,753 | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 15,088 |
820 | 875 | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,890 | |
CWIP | 285 | 534 | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 412 |
Investments | 60 | 186 | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 127 |
2,587 | 3,427 | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 6,659 | |
Total Assets | 3,753 | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 15,088 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
153 | 599 | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | |
-247 | -418 | -2,113 | -869 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | |
20 | 86 | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | |
Net Cash Flow | -73 | 268 | -90 | 437 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 78 | 96 | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 |
Inventory Days | 364 | 297 | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 |
Days Payable | 421 | 421 | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 |
Cash Conversion Cycle | 22 | -28 | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 |
Working Capital Days | 33 | 42 | 54 | -1 | 28 | 20 | -17 | -2 | 82 | 89 | 74 | 53 |
ROCE % | 33% | 35% | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23h - Schedule of Investors Meet under SEBI regulations.
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
17 Feb - Penalty of ₹ 20,96,197 imposed by tax authority.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
14 Feb - Schedule of investor meet on 19-Feb-25.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 Feb - Of Schedule of Investors Meet under Regulation 30 of SEBI (LODR) Regulations, 2015
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
7 Feb - Of Schedule of Investors Meet under Regulation 30 of SEBI (LODR) Regulations, 2015
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Jan 2025TranscriptPPT
-
Oct 2024TranscriptPPTREC
-
Jul 2024TranscriptPPT
-
May 2024TranscriptPPT
-
Feb 2024TranscriptPPT
-
Aug 2023TranscriptPPT
-
May 2023TranscriptPPT
-
Sep 2022TranscriptNotesPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
May 2018TranscriptNotesPPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Oct 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
May 2016TranscriptPPT
Product Segments Q2 FY25
1) Branded Generics (74%): [1] The company’s branded generics business focuses on the manufacturing pharmaceutical products under its brand names catering to various therapeutic segments including cardiovascular, central nervous system, gastrointestinal, vitamin mineral nutrients, dermatology, diabetes, pain management and gynecology. Its branded generic medicines are marketed in key regions including India and Brazil. [2]